ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 3

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

July 2, 2024

Ticiana A. Leal, MD, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Afshin Dowlati, MD, Tarita O. Thomas, MD, PhD

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

Now Viewing

EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP. 4: Examining 3-Year Update Data from the CASPIAN Trial

EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP. 12: Examining Key Data from DAREON-8

EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
1. Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
1. What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?